EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Omalizumab Treated Urticaria Patients Display T Cell and Thrombocyte‐Associated Gene Regulation

Anna Smola iD, Heike C Hawerkamp iD, Péter Oláh, Andreas Kislat, Nicole Duschner, Bernhard Homey, Stephan Meller

Immunity, Inflammation and Disease · 2025

DOI: 10.1002/iid3.70132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2025. Verfasst von Anna Smola und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany. Hauptthemen laut MEDLINE: Omalizumab, T-Lymphocytes, Gene Expression Regulation, Blood Platelets. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was funded by an independent grant from Novartis AG..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic spontaneous urticaria (CSU) is a debilitating inflammatory skin disease with a prevalence of approximately 1% of the population. It is characterized by recurrent itchy wheals and/or angioedema for more than 6 weeks without known triggers leading to a high quality of life impairment. The pathogenesis of CSU remains not fully understood.

Objective

This study aimed to explore the pathomechanism of CSU beyond mast cells and IgE‐dependent histamine release and to identify possible biomarkers for the disease and its treatment.

Methods

We investigated a patient cohort in the first month of omalizumab treatment regarding the IgE levels and changes in gene and miRNA expression in peripheral blood. The cohort was divided into responders and nonresponders (depending on the score of the urticaria control test) and compared to a group of healthy controls.

Results

Our messenger RNA and microRNA microarray analyses revealed the greatest changes in expression levels on Day 2 after the first omalizumab dose.

Conclusion

We identified several genes and miRNAs of interest, most of which have not been described to be linked to CSU so far, underlining, for example, to T cell involvement or even suggesting platelet involvement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabT-LymphocytesGene Expression RegulationBlood PlateletsAnti-Allergic AgentsChronic UrticariaUrticariaHumansMaleFemaleAdultMiddle AgedMicroRNAsImmunoglobulin E

Substanzen

OmalizumabMicroRNAsAnti-Allergic AgentsImmunoglobulin E

Autor:innen und Institutionen

  • Department of Dermatology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
  • Department of Dermatology, Venereology and Oncodermatology, University of Pécs, Pécs, Hungary.

ORCID-Profile: Anna Smola, Heike C Hawerkamp

Förderung

  • This study was funded by an independent grant from Novartis AG.

Zitieren

APA

Smola, A., Hawerkamp, H. C., Oláh, P., Kislat, A., Duschner, N., Homey, B., & Meller, S. (2025). Omalizumab Treated Urticaria Patients Display T Cell and Thrombocyte‐Associated Gene Regulation. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.70132

Vancouver

Smola A, Hawerkamp HC, Oláh P, Kislat A, Duschner N, Homey B, et al. Omalizumab Treated Urticaria Patients Display T Cell and Thrombocyte‐Associated Gene Regulation. Immunity, Inflammation and Disease. 2025. doi:10.1002/iid3.70132

BibTeX
@article{Smola2025,
  author = {Smola, Anna and Hawerkamp, Heike C and Oláh, Péter and Kislat, Andreas and Duschner, Nicole and Homey, Bernhard and Meller, Stephan},
  title = {Omalizumab Treated Urticaria Patients Display T Cell and Thrombocyte‐Associated Gene Regulation},
  journal = {Immunity, Inflammation and Disease},
  year = {2025},
  doi = {10.1002/iid3.70132}
}
Kostenlos starten →